This study aimed to investigate differences in clinical characteristics and risk factors for mortality between CADM and CDM and to clarify the distribution and impact of anti-MDA5 antibodies in patients with these conditions. The gene discussed is IFIH1; the disease is clinically amyopathic dermatomyositis.